AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 Fred Hutch Center For Community Health Promotion, Sunnyside, Washington, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
11 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
12 Mayo Clinic, Jacksonville, Jacksonville, Florida, United States
13 King Hussien Cancer Center, Amman, Jordan, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
14 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
15 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
16 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Myeloablative total body irradiation (TBI)-based conditioning combined with chemotherapy represents the historical gold standard for adult acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). While TBI provides excellent anti-leukemic control, it carries a substantial burden of regimen-related toxicities and non-relapse mortality (NRM). With the widespread adoption of post-transplant cyclophosphamide (PTCy), there is growing interest in whether non-TBI chemotherapy-based myeloablative conditioning (MAC) can serve as a safer alternative within a uniform HLA-mismatched platform.
Methods:
We evaluated 1,082 adult patients (aged ≥18 years) with ALL who underwent their first allo-HCT between 2017 and 2021 using an HLA-mismatched donor (haploidentical related or mismatched unrelated) and uniform PTCy-based graft-versus-host disease (GVHD) prophylaxis, reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) under protocol [P-6144]. All recipients received myeloablative conditioning, stratified into TBI-based MAC (dose >800 cGy; n=155) versus non-TBI chemotherapy MAC (n=927). Primary endpoints were overall survival (OS), progression-free survival (PFS), and GVHD-free relapse-free survival (GRFS). Secondary endpoints were cumulative incidence of relapse (CIR) and non-relapse mortality (NRM). Multivariable Cox proportional hazards and Fine–Gray competing-risk models adjusted for recipient age, HCT-Comorbidity Index (HCT-CI), Karnofsky performance status (KPS), graft source, disease risk index, pre-transplant measurable residual disease (MRD) status, and Philadelphia chromosome positivity. A two-sided p-value <0.05 was considered statistically significant.
Results:
A total of 1,082 patients were included (TBI-based MAC n=155 [14.3%]; non-TBI chemotherapy MAC n=927 [85.7%]). Patients receiving TBI-based MAC were younger (median age 28 vs 38 years, p<0.001), more often had KPS 90–100% (76.1% vs 67.0%, p=0.034), and lower comorbidity burden (HCT-CI = 0: 54.8% vs 42.9%, p=0.008). Bone marrow grafts were more frequent with TBI (29.7% vs 20.0%, p=0.006). Disease subtype distribution differed (T-ALL more common with TBI: 31.6% vs 20.6%, p=0.011).
In unadjusted 2-year analyses, TBI-based MAC was associated with superior OS (56.5% vs 49.8%, p=0.041) and lower CIR (24.5% vs 36.2%, p=0.004). Two-year NRM was higher with TBI but not statistically significant (25.4% vs 21.5%, p=0.312). PFS favored TBI (50.1% vs 42.3%, p=0.032); GRFS was similar (27.2% vs 25.4%, p=0.584). After multivariable adjustment, non-TBI chemotherapy MAC showed no significant difference in OS (aHR 1.04, 95% CI 0.85–1.27, p=0.712), PFS (aHR 1.12, 95% CI 0.91–1.38, p=0.284), or GRFS (aHR 0.98, 95% CI 0.82–1.17, p=0.822) compared with TBI. Competing-risks modeling revealed a biologic trade-off: non-TBI regimens carried a higher adjusted risk of relapse (aHR 1.31, 95% CI 1.02–1.68, p=0.034) that was offset by a lower point estimate for NRM (aHR 0.78, 95% CI 0.58–1.05, p=0.091).
Conclusions:
In adult patients with ALL undergoing HLA-mismatched or haploidentical allo-HCT with a modern PTCy backbone, non-TBI chemotherapy-based MAC yields equivalent adjusted OS, PFS, and GRFS compared with TBI-based regimens. The superior anti-leukemic protection of myeloablative TBI is counterbalanced by its added regimen-related toxicities. These data support that omitting TBI in favor of a chemotherapy-only myeloablative protocol within a PTCy platform is a safe and effective strategy, particularly for older patients or those with notable comorbidities.